Will the advent of antileukotriene therapy lead to changes in asthma treatment guidelines?
Will the advent of antileukotriene therapy lead to changes in asthma treatment guidelines?
Leukotrienes are bronchoconstrictor and pro-inflammatory mediators implicated in asthma. Drugs that block leukotriene synthesis or activity are set to become the first major breakthrough in asthma therapy for 25 years. Antileukotriene drugs block bronchoconstriction after challenge with allergen, aspirin or exercise, and in clinical trials in patients with asthma they improve baseline lung function, reduce night-time awakenings, improve daytime symptom scores and halve the number of acute exacerbations. They are likely to be used as oral prophylactic therapy to reduce the dosage of corticosteroids right across the spectrum of asthma severity. Further studies on possible long term anti-inflammatory effects are currently in progress.
167-174
Sampson, Anthony P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Corne, Jonathan M.
f2d716a7-31f0-40a3-afb3-d86b850634ee
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
1997
Sampson, Anthony P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Corne, Jonathan M.
f2d716a7-31f0-40a3-afb3-d86b850634ee
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Sampson, Anthony P., Corne, Jonathan M. and Holgate, Stephen T.
(1997)
Will the advent of antileukotriene therapy lead to changes in asthma treatment guidelines?
BioDrugs, 7 (3), .
(doi:10.2165/00063030-199707030-00001).
Abstract
Leukotrienes are bronchoconstrictor and pro-inflammatory mediators implicated in asthma. Drugs that block leukotriene synthesis or activity are set to become the first major breakthrough in asthma therapy for 25 years. Antileukotriene drugs block bronchoconstriction after challenge with allergen, aspirin or exercise, and in clinical trials in patients with asthma they improve baseline lung function, reduce night-time awakenings, improve daytime symptom scores and halve the number of acute exacerbations. They are likely to be used as oral prophylactic therapy to reduce the dosage of corticosteroids right across the spectrum of asthma severity. Further studies on possible long term anti-inflammatory effects are currently in progress.
This record has no associated files available for download.
More information
Published date: 1997
Additional Information:
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
Identifiers
Local EPrints ID: 455207
URI: http://eprints.soton.ac.uk/id/eprint/455207
ISSN: 1173-8804
PURE UUID: 67aea8d5-09a3-41a5-84f4-2276b102c8ec
Catalogue record
Date deposited: 15 Mar 2022 17:33
Last modified: 17 Mar 2024 02:43
Export record
Altmetrics
Contributors
Author:
Jonathan M. Corne
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
